Clinical Trials - IRD

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT07185256Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)RECRUITINGPHASE1, PHASE22025-092030-082030-08
NCT05616793Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD)RECRUITINGPHASE1, PHASE22023-06-152028-06-152028-06-15